Opens in a new tab

Stopping GLP-1 Drugs: What Happens to Weight, A1C and Blood Pressure

Table of Content

Stopping GLP-1 drugs: a doctor reviews an A1C blood test report and weight trend chart with a patient

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

What happens when you stop a GLP-1 drug like Wegovy, Ozempic, Mounjaro or Zepbound? It is one of the most common questions in obesity care, because many people do stop, whether because of cost, insurance coverage or side effects. A Cleveland Clinic study announced on November 14, 2026, and presented on November 15 at ObesityWeek 2026, gives one of the clearest real-world answers so far. It tracked more than 20,000 patients after they stopped semaglutide or tirzepatide and compared what happened to their weight, A1C and blood pressure depending on what they did next. Stopping with no follow-on treatment kept the least benefit. Here is what the study found, what it cannot tell us, and the blood tests that show how your body is doing after you stop.

What the Cleveland Clinic study found

A team led by Hamlet Gasoyan, PhD, analyzed electronic health records of 20,486 Cleveland Clinic patients who took semaglutide (the drug in Ozempic and Wegovy) or tirzepatide (the drug in Mounjaro and Zepbound) for at least three months between 2021 and 2023 and then discontinued it. According to Cleveland Clinic, the study is published in eClinicalMedicine. Researchers compared five paths over two years.

Strategy after stoppingAverage weight loss at two years
Bariatric surgeryAbout 28%
Switching between semaglutide and tirzepatideAbout 16%
Going back on the original drugNearly 11%
Another obesity medicationAbout 8%
Stopping with no further treatmentAbout 4%

The figures in the table are those reported by Cleveland Clinic. In people with type 2 diabetes, A1C improved most after bariatric surgery, followed by switching drugs, staying on the original drug and moving to another obesity medication. Stopping with no follow-on treatment brought only minimal improvement in blood sugar control at one year. Blood pressure followed the same pattern: patients with hypertension saw larger drops when they continued treatment than when they stopped.

Why this matches earlier research

GLP-1 drugs work while you take them. They curb appetite and improve how the body handles insulin, but they do not permanently reset weight regulation. Earlier studies pointed the same way:

  • In the SURMOUNT-4 trial, published in JAMA, people who lost an average of about 21% of their body weight on tirzepatide regained about 14% within a year after switching to placebo, while those who stayed on the drug kept losing.
  • A University of Oxford meta-analysis in The BMJ (January 2026; 37 studies, 9,341 participants) found that weight came back faster after stopping weight-loss medicines than after ending a behavioral weight program, and projected that cardiometabolic markers, including A1C, glucose, cholesterol and blood pressure, return to their starting levels within about a year and a half.
  • A meta-analysis of 18 randomized trials in eClinicalMedicine (late 2025) described a "metabolic rebound" after GLP-1 drugs are stopped: weight regain, higher A1C and fasting glucose, and a rise in systolic blood pressure.

What is new in the Cleveland Clinic work is that it reflects everyday practice, and it compares outcomes according to what patients did after stopping.

What the study cannot tell us

This is an analysis of medical records, not a randomized trial. People who had surgery or switched drugs may differ from those who stopped everything, in motivation, reasons for stopping, insurance coverage or side effects. So the study shows associations; it does not prove that one strategy causes a better result. Cleveland Clinic did not report cholesterol results in its announcement, and the full paper was not yet indexed when this news was published, so the numbers here come from the official release.

Context matters too. According to Cleveland Clinic, citing the Gallup National Health and Well-Being Index, the share of U.S. adults using GLP-1 drugs for weight loss rose from 3% in 2024 to 11% in 2026. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that obesity medicines are meant to be used alongside healthy eating and physical activity, and that people will probably regain some weight after they stop taking them.

Which tests can monitor or screen for this?

The scale does not tell the whole story. After stopping a GLP-1 drug, routine blood work shows whether the metabolic gains are holding:

  • Hemoglobin A1C reflects your average blood sugar over the past two to three months. It is the most useful marker for spotting a rebound, especially if you have diabetes or prediabetes. The CDC defines below 5.7% as normal, 5.7% to 6.4% as prediabetes and 6.5% or above as diabetes.
  • Fasting blood glucose gives a snapshot of the day and complements A1C.
  • A lipid panel (triglycerides, LDL and HDL cholesterol): triglycerides often climb back with weight.
  • Liver enzymes such as ALT and AST, since fatty liver disease tends to track body weight.
  • Creatinine and eGFR, sometimes with cystatin C, to check kidney function, especially if you have diabetes or high blood pressure.

Many of these come together in a comprehensive metabolic panel. How often to recheck depends on your health, and your clinician will set the schedule.

Recent research advances

Research over the past three years has changed how doctors think about these medicines. Obesity is increasingly treated as a chronic condition that needs long-term management rather than a short course of treatment. Researchers now know that stopping is common, and they are testing ways to soften its effects: tapering the dose gradually instead of stopping abruptly, switching to a different drug, and adding stronger nutrition and exercise support. A separate Cleveland Clinic study, published in November 2026 in Annals of Surgery, found that bariatric surgery still led to meaningful weight loss in people who could not tolerate these drugs or did not lose enough weight on them. Other teams are working on ways to predict, before treatment ends, who is most likely to regain weight quickly.

When to see a doctor

  • Before you stop a GLP-1 drug, to plan what comes next.
  • If you have diabetes and your blood sugar readings rise after stopping.
  • If you regain weight quickly, your blood pressure goes up or your blood work worsens.
  • Right away, or call 911, if you have severe, persistent belly pain, with or without vomiting, while on treatment, because it can be a sign of pancreatitis.

Glossary

  • GLP-1 drug: a medicine that mimics a gut hormone that regulates appetite and insulin release, such as semaglutide or tirzepatide.
  • Hemoglobin A1C: the share of hemoglobin bound to sugar, which reflects average blood sugar over the past two to three months.
  • Metabolic rebound: the return of weight, blood sugar or blood pressure toward pre-treatment levels after a medicine is stopped.
  • Bariatric surgery: weight-loss surgery, such as gastric bypass or sleeve gastrectomy.
  • Observational study: a study that analyzes existing data without randomly assigning treatments; it shows associations, not cause and effect.

Frequently asked questions

Do you always regain weight after stopping Wegovy or Zepbound?

Not always all of it, but regain is common. In the Cleveland Clinic study, people who stopped everything kept an average loss of only about 4% of their body weight at two years, far less than those who had a follow-on treatment.

Does blood sugar go up after stopping a GLP-1 drug?

Often, especially in people with type 2 diabetes. Meta-analyses show A1C and fasting glucose rising after GLP-1 drugs are stopped. A follow-up A1C test helps catch it early.

Should you taper off instead of stopping suddenly?

Clinical trials are testing gradual tapering, but there is no firm answer yet. How to stop is a decision to make with your prescriber.

Is switching from semaglutide to tirzepatide a good option?

In the Cleveland Clinic study, switching between the two drugs was linked to good results. That is an association, not proof, and the choice depends on tolerance and coverage.

What blood tests should I get after stopping?

Usually an A1C, a fasting glucose and a lipid panel, sometimes liver enzymes and kidney function. Your clinician will tailor the list to you.

Sources

Further reading

Understand your own blood test results with AI DiagMe

Just got an A1C, a fasting glucose or a lipid panel after stopping your GLP-1 medication? Upload your blood test to AI DiagMe and get a clear, personalized explanation of every value in minutes, so you can prepare your questions for your doctor.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practicing hospital physicians in specialties such as hematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr. Claude Tchonko is a hematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specializes in the management of hematologic malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimization of care pathways in onco-hematology.

    Author of a reference work, “Lymphoid Hematologic Malignancies in Mali”, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Hematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Hematology and an inter-university diploma (DIU) in Onco-Hematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming Soon